Management of Menorrhagia in Women with a Levonorgestrel IUD and Uterine Fibroids

Initial Evaluation

Ultrasound assessment of fibroid characteristics – Size, number, and location (submucosal, intramural, subserosal) should be documented because submucosal fibroids are less responsive to hormonal medical therapy. 1
Baseline hemoglobin measurement – Quantify anemia to determine the need for iron supplementation before initiating treatment. 2

Levonorgestrel‑releasing intrauterine system (LNG‑IUS) – Recommended as the most effective first‑line medical option for women with menorrhagia and fibroids; it reduces menstrual blood loss to a degree comparable with endometrial ablation or hysterectomy while preserving fertility and being reversible. 2
Tranexamic acid (non‑hormonal) – Reduces menstrual blood loss by approximately 20 %–60 % and is suitable for patients who cannot or do not wish to use hormonal agents. 2
Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Provide a 20 %–60 % reduction in bleeding and also alleviate dysmenorrhea. 2
Combined oral contraceptives – Offer first‑line bleeding control together with reliable contraception for patients desiring both effects. 2

GnRH antagonists (e.g., relugolix, elagolix, linzagolix) with add‑back hormone therapy – Decrease menstrual bleeding and fibroid volume by 18 %–50 % over 3–4 months; add‑back estrogen/progestin (low dose) is mandatory to prevent bone mineral density loss and severe hypo‑estrogenic symptoms. [3][4]
Fertility suppression during GnRH antagonist use – These agents temporarily suppress ovulation; menstrual symptoms typically recur rapidly after discontinuation. [3][4]

Failure of optimal medical therapy – Consider surgery or uterine‑sparing interventions after 3–6 months of adequate trial with LNG‑IUS or GnRH antagonists without satisfactory response. 5
Symptomatic submucosal fibroids – Hysteroscopic myomectomy is indicated for submucosal lesions that deform the uterine cavity, offering short hospitalization and rapid return to activity. 1
Dominant compressive symptoms – When bleeding is not the sole issue, prioritize definitive surgical options or uterine artery embolization (UAE). 3
Uterine artery embolization outcomes – Clinical success rates range from 81 % to 100 %; improvement in menorrhagia occurs in ~83 % of patients at 3 months, with a 20 %–25 % symptom recurrence at 5–7 years. Permanent amenorrhea occurs in <2 %–3 % of women <45 years and up to 20 % in women >45 years. 5

Short‑course GnRH antagonist pre‑treatment (3–4 months) – Reduces fibroid size and operative complexity before definitive surgery. 3
Concurrent iron supplementation – Corrects anemia identified during initial evaluation to optimize peri‑operative status. 2
Timing of surgery – Schedule definitive surgery promptly after GnRH antagonist course because fibroids tend to regain size quickly once therapy stops. [3][4]

Prolonged GnRH antagonist use without add‑back therapy – Leads to significant bone loss; add‑back hormones are required throughout treatment. [2][4]
Relying on GnRH antagonists as a definitive long‑term solution – They are unsuitable for chronic management without transition to a definitive modality (surgery, UAE, or LNG‑IUS). [3][4]
Expecting optimal response of submucosal fibroids to LNG‑IUS alone – Intramural/subserosal fibroid burden or coexistent adenomyosis diminishes the efficacy of LNG‑IUS and may necessitate additional interventions. 1
Underestimating risk of permanent amenorrhea after UAE – Counsel patients, especially those >45 years, about the higher (<20 %) risk of lasting amenorrhea. 5

GnRH therapy (agonist or antagonist) can halt excessive vaginal bleeding and raise hemoglobin levels before surgery, especially in patients with severe anemia, enabling procedures to be performed when patients are in a more stable condition. 6

Hypoestrogenic softening of small intramural fibroids may render them non‑palpable during myomectomy, increasing the risk of incomplete excision and giving the impression of rapid recurrence. 6, 7
Evidence supporting a reduction in intra‑operative blood loss or shorter operative time with pre‑treatment is limited. 6

GnRH agonist therapy leads to an average fibroid volume reduction of about 35 %; however, the corresponding decrease in fibroid diameter is smaller than predicted by simple geometric calculations. 7

After myomectomy, a waiting interval of 2–3 months before attempting conception is advised to allow uterine incisions to heal and to minimize the risk of myometrial scar disruption. 7

Recurrence of fibroids after myomectomy occurs in roughly one‑third of patients, with rates influenced by the number of removed tumors and the duration of follow‑up. 6
Patients should be counseled that myomectomy offers only temporary symptom relief and does not eliminate the underlying hereditary predisposition to develop fibroids. 6